1. Introduction
===============

Compounds containing the quinoxaline nucleus exhibit a broad spectrum of biological activity such as antibacterial \[[@B1-pharmaceuticals-03-02416],[@B2-pharmaceuticals-03-02416],[@B3-pharmaceuticals-03-02416]\], antifungal \[[@B4-pharmaceuticals-03-02416],[@B5-pharmaceuticals-03-02416]\], antiviral \[[@B6-pharmaceuticals-03-02416]\], anticancer \[[@B7-pharmaceuticals-03-02416]\], antituberculosis \[[@B8-pharmaceuticals-03-02416]\], antimalarial \[[@B9-pharmaceuticals-03-02416]\] and anti-inflammatory properties \[[@B10-pharmaceuticals-03-02416]\]. Many researchers have reported the synthesis and biological activity of quinoxaline derivatives \[[@B11-pharmaceuticals-03-02416],[@B12-pharmaceuticals-03-02416],[@B13-pharmaceuticals-03-02416],[@B14-pharmaceuticals-03-02416]\]. In the light of these facts we decided to synthesize some new quinoxaline derivatives incorporating aromatic aldehyde and aromatic amine moieties attached to a 2-hydroxy-3-methylquinoxaline nucleus with an ether linkage followed by the treatment with aromatic amines or aromatic aldehydes to afford Schiff bases in the hope of obtaining better antimicrobial agents. All the synthesized compounds were screened for their antimicrobial activity.

2. Result and Discussion
========================

2.1. Synthesis
--------------

The chemical synthesis ([Scheme 1](#pharmaceuticals-03-02416-f001){ref-type="scheme"}) was initiated with the reaction of *o*-phenylenediamine (**1**) with ethyl pyruvate in *n*-butanol to yield 2-hydroxy-3-methylquinoxaline (**2**), which on treatment with POCl~3~ yielded 2-chloro-3-methylquinoxaline (**3**). A mixture of compound **3** and 4-hydroxy benzaldehyde was next refluxed in acetonitrile for 30 hours to afford 2-(*p*-formylphenoxy)-3-methyl quinoxaline (**4**) as an intermediate. Mixtures of compound **4** and various substituted aromatic amines were refluxed in ethanol to afford 2-\[4-(substituted benziminomethyl)phenoxy\]-3-methylquinoxalines **5a--e**. In another set of reactions, compound **3** was refluxed with *p*-aminophenol in acetonitrile for 30 hours to yield 4-(2-methylquinoxalin-3-yloxy) benzamine (**6**) as a second intermediate. Compound **6** was refluxed with different substituted aromatic aldehydes in order to prepare compounds **7a--e**. The structures of all newly synthesized compounds were elucidated on the basis of their spectral and analytical data.

The IR spectrum of compound **4** showed absorption bands at 3,038 cm^−1^due to CH~3~ stretching, at 1,600 cm^−1^ due to C=N stretching, a strong band at 1,699 cm^−1^due to an aldehyde function and a band at 1,222 cm^−1^due to the C-O-C aryl ether (C-O stretching). Its ^1^H-NMR spectrum showed a singlet (3H) at δ 2.870 due to CH~3~ protons, a broad set of multiplets between δ 6.6 - 8.0 (8H) due to aromatic hydrogens and a sharp singlet at δ 10.07 due to an aldehyde proton. This indicated that a free aldehyde function was present which could be reacted with substituted aromatic amines to form Schiff bases. Similarly the IR spectrum of compound **6** showed two bands at 3,466 cm^−1^and 3,425 cm^−1^due to primary amine N-H stretching, while other bands at 3,041 cm^−1^ due to CH~3~ stretching and a band at 1,220 cm^−1^ due to (C-O-C) aryl ether were also present. In the case of the intermediate **6**, the ^1^H-NMR spectrum showed a sharp singlet at δ 2.825 due to the protons of a CH~3~ group attached to the quinoxaline ring, a broad D~2~O exchangeable singlet at δ 3.742 due to NH~2~ protons, and a characteristic aromatic proton multiplet between δ 6.77-8.00 ppm. A singlet at around δ 8.40-9.03 due to presence of the (**CH**=N-) group in the compounds **5a--e** and **7a--e** clearly suggested the formation of the expected Schiff bases. IR, ^1^H-NMR spectra and elemental analytical data of compounds **5a--e** and **7a--e** confirmed the structures of the newly synthesized compounds.

![Synthesis of some new quinoxaline derivatives.](pharmaceuticals-03-02416-g001){#pharmaceuticals-03-02416-f001}

2.2. Antibacterial Activity
---------------------------

The antibacterial activity was determined by the disc diffusion method at the concentration of 50 µg per disk. All the synthesized compounds were tested *in vitro* for their antibacterial activity against microorganisms such as *Staphylococcus aureus*, *Bacillus subtilis* (Gram positive), *Escherichia coli*, *Pseudomonas aeruginosa* (Gram negative), using ciprofloxacin as standard antibacterial. The results of activity, presented in the [Table 1](#pharmaceuticals-03-02416-t001){ref-type="table"} suggested that compounds **4**, **5a**, **5c**, **5d**, **5e**, **7a** and **7c** were highly active against both Gram positive and Gram negative bacteria, among them compounds **5c**, **5d**, **7a**, **7c**, and **7e** were specifically highly active against *E. coli*. Compound **5a** possessed no activity against *Bacillus subtilis*, Compounds **5b**, and **5c** showed no activity against *Pseudomonas aeruginosa.* Compound **7d** showed no activity against *Escherichia coli and Pseudomonas aeruginosa.* The rest of tested compounds were found to have moderate antibacterial activity. The high activity of compounds **4**, **5a**, **5c**, **5d**, **5e** and **7c** could be explained on the basis of the contributions of incorporated aromatic ring and --CH~3~ groups, which we know should increase the lipophilicity of the compounds. This increase in lipophilicity would help their permeability through the microbial cell wall resulting in higher activity. Compound **5d** may be considered the analogue of benzoic acid (a known antimicrobial) due the presence of the --COOH group.

2.3. Antifungal Activity
------------------------

The antifungal activity was tested against strain such as *A. niger* and *C. albicans*, using fluconazole as standard antifungal. Compounds **4**, **6**, and **7a** showed moderate activity against both strains. Compounds **5a**, **5b**, **5c**, **5d** and **5e** showed no activity against *A. niger*. Compounds **7b**, **7c**, **7d** and **7e** showed moderate activity against *A. niger* but no activity against *C. albicans.*

pharmaceuticals-03-02416-t001_Table 1

###### 

Results of antimicrobial activity of the compounds, zones of inhibition (in mm).

  Compounds           Zone of Inhibition                                       
  ------------------- -------------------- -------- -------- -------- -------- --------
  **4**               \+ + +               \+ +     \+ +     \+ +     \+ +     \+ +
  **5a**              \+ +                 \-       \+ + +   \+ +     \-       \-
  **5b**              \+ +                 \+ +     \+ +     \-       \-       \-
  **5c**              \+ + +               \+ +     \+ + +   \-       \-       \+ +
  **5d**              \+ + +               \+ + +   \+ + +   \+ +     \-       \-
  **5e**              \+ + +               \+ +     \+ +     \+ +     \-       \+ +
  **6**               \+ +                 \+ +     \+ +     \+ +     \+ +     \+ +
  **7a**              \+ + +               \+ + +   +++      ++       \+ +     \+ +
  **7b**              \+ +                 \+ +     \+ +     \+ +     \+ +     \-
  **7c**              \+ + +               \+ +     \+ + +   \+ +     \+ +     \-
  **7d**              \+ +                 \+ +     \-       \-       \+ +     \-
  **7e**              \+ +                 \+ +     \+ + +   \+ +     \+ +     \-
  **Ciprofloxacin**   \+ + +               \+ + +   \+ + +   \+ + +            
  **Fluconazole**                                                     \+ + +   \+ + +

Key to symbols: - inactive (inhibition zone \< 6 mm); slightly active = + (inhibition zone 7--9 mm); moderately active = + + (inhibition zone 10-13 mm); highly active = + + + (inhibition zone \> 14 mm).

3. Experimental
===============

3.1. General
------------

All recorded melting points were determined on a laboratory melting point apparatus using the capillary method and are uncorrected. Purity of the compounds was checked by thin layer chromatography using silica gel-G on micro slide glass plates and spots were detected under iodine vapor. IR spectra were recorded in KBr disk on a Shimadzu FTIR-8400 spectrophotometer and ^1^H-NMR spectra on a JEOL FT-NMR Spectrometer (300 MHz) using TMS as an internal standard. All chemical shift values were recorded as δ (ppm).

### 3.1.1. Synthesis of 3-methylquinoxalin-2-(1H)-one (**2**)

o-Phenylenediamine (10.8 g, 0.10 M) was dissolved in *n*-butanol (300 mL) with warming. Ethyl pyruvate (11.6 g, 15 mL, 0.10 M) was dissolved separately in *n*-butanol (100 mL) and added to the former solution with constant stirring. The solution was set aside for 30 min, and then it was heated for 1 hour on a water bath. On cooling, the crystals that separated were filtered, washed with *n*-hexane and purified by recrystallization from ethanol to yield colorless, needle-shaped crystals of 2-hydroxy-3-methylquinoxaline. Yield 80%; m.p. 246 °C (\[[@B15-pharmaceuticals-03-02416],[@B16-pharmaceuticals-03-02416]\] m.p. 245 °C); IR (KBr, cm^−1^): 3,008 (2° amide N--H), 2,968 (methyl group C-H), 1,665 (amide C=O), and 1,610 (aromatic nucleus C=C multiple bond).

### 3.1.2. Synthesis of 2-chloro-3-methylquinoxaline (**3**)

2-Hydroxy-3-methylquinoxaline (16.0 g, 0.10 M) in POCl~3~ (60 mL) was refluxed for 90 min. Then the excess of POCl~3~ was distilled off and the residue was cooled to room temperature and added to crushed ice taken in a 1 L beaker. The mixture was made alkaline by adding 2% NaOH solution to isolate the product. The crude product was recrystallized from petroleum ether (40--60 °C), to yield the crystals of 2-chloro-3-methylquinoxaline (**3**). Yield 60%; m.p. 88 °C (lit. \[[@B17-pharmaceuticals-03-02416]\] m.p. 86--87 °C); IR (KBr) data clearly showed the disappearance of the amide C=O stretching vibration and the appearance of an aryl halide C-Cl stretching vibration at 1,038.52 cm^−1^.

### 3.1.3. Synthesis of 4-(2-methylquinoxalinyloxy) benzaldehyde (**4**)

*p*-Hydroxybenzaldehyde (0.1.22 g, 0.01 M) was dissolved in acetonitrile (50 mL) taken in a 250 mL round bottomed flask. Anhydrous K~2~CO~3~ (2.0 g) was added to the mixture, which was refluxed for 1 hour, then 2-chloro-3-methylquinoxaline (1.785 g, 0.01 M) was added and the mixture was further refluxed for 30 hours. At the end of the reaction time, the mixture was filtered and excess of acetonitrile was distilled off to get the product. The crude product was treated with 2%NaOH solution to dissolve any unreacted *p*-hydroxybenzaldehyde. The product was filtered, washed with distilled water to remove traces of alkali and recrystallized from ethanol to get crystals of 4-(2-methylquinoxalinyloxy) benzaldehyde (**4**). Yield 70%; m.p. (116--117 °C); IR (KBr, cm^−1^): 1,736 (aldehyde C=O), 1,222 (ether C-O); ^1^H-NMR (CDCl~3~): 2.880 (s, 3H, CH~3~ attached to a quinoxaline ring), 7.288--8.047 (m, 8H, aromatic protons); 10.076 (s, 1H, aldehyde proton).

3.2. General procedure for the synthesis of 2-\[4-(substituted benziminomethyl) phenoxy\]-3-methyl-quinoxalines *5a--e*
-----------------------------------------------------------------------------------------------------------------------

Compound **4** (0.01 M) and substituted aromatic amines (0.01 M) in ethanol (25mL) containing a catalytic amount of glacial acetic acid were refluxed for an appropriate time to complete the reaction, as monitored by TLC. After completion of the reactions, the flask contents were cooled and the separated crystalline compound was filtered, washed with a little ethanol and recrystallized from ethanol.

### 3.2.1. *N*-\[(4-(2-Methylquinoxalin-3-yloxy)-phenyl)-methylenebenzamine (**5a**)

IR (KBr, cm^−1^): 3,060 (methyl C-H), 1,578 (-C=N-), 1,222 (ether C-O); ^1^H-NMR (CDCl~3~): 2.843 (s, 3H, CH~3~ attached to quinoxaline ring), 7.226--8.033 (m, 13H, Ar-H), 8.507 (s, 1H, CH=N-); MS: m/z 339. Anal. calc. for C~22~ H~17~ N~3~ O: C 77.86, H 5.05, N 12.38%. Found: C 77.65, H 5.20, N 12.52%.

### 3.2.2. \[(4-(2-Methylquinoxalin-3-yloxy)-phenyl)-methylene)-2-chlorobenzamine (**5b**)

IR (KBr, cm^−1^) 3,059, (methyl C-H), 1,583, (-C=N-), 1,222, (ether C-O) and 1,038, (aryl C-Cl). ^1^H NMR (CDCl~3~): 2.847, (s, 3H, CH~3~ attached to quinoxaline ring), 7.044--8.073(12H, Ar-H), 8.437, (s, 1H, CH=N-). MS: m/z 373. Anal. Calculated for C~22~ H~16~ Cl N~3~ O: C 70.68, H 4.31, N 11.24%.Found: C 70.75, H 4.20, N 11.46%.

### 3.2.3. *N*-\[{4(2-Methylquinoxalin-3-yloxy)-phenyl}-methylyne\]-4-methylbenzeneamine (**5c**)

IR (KBr, cm^−1^): 1,578 (-C=N), 1,223 (ether C-O). Disappearance of band at 1,735.85 for aldehyde indicated the formation of --CH=N- group.^1^H NMR (CDCl~3~): 2.838 (s, 3H, CH~3~ attached to quinoxaline ring), 2.387 (s, 3H, CH~3~ attached to benzene), 7.148--8.018 (m, 12H, Ar-H) 8.511, (s, 1H, CH=N-).MS: m/z 353. Anal. Calculated for C~23~ H~19~ N~3~ O: C 78.16, H 5.42, N 11.89%.Found: C 78.08, H 5.54, N 11.78%.

### 3.2.4. 4-((4-(2-Methylquinoxalin-3yloxy)-phenyl) - methylene-aminobenzoicacid (**5d**)

IR (KBr, cm^−1^) 2,927 (methyl C-H), 1,686 (carboxylic C=O), 1,583 (-C=N-), 1,222 (ether C-O). ^1^H NMR (DMSO): 2.767 (s, 3H, CH~3~ attached to quinoxaline ring), 7.121--8.094(m, 12H, Ar-H), 8.686, (s, 1H, CH=N-), 12.836 (s, 1H, COOH). MS: m/z 383. Anal. Calculated for C~23~ H~17~ N~3~ O~3~: C 72.05, H 4.47, N 10.96%.Found: C 71.95, H 4.22, N 11.00%.

### 3.2.5. *N*-\[(2-methylquinoxalin-3-yloxy)-phenyl)-methylene)-2, 6-dimethylbenzamine (**5e**)

IR (KBr, cm^−1^) 2,919 (methyl C-H), 1,577 (-C=N-), 1,224 (ether C-O). ^1^H NMR (CDCl~3~): 2.846(s, 3H, CH~3~ attached to quinoxaline ring), 2.336 and 2.317 (d, 6H, CH~3~ on aromatic benzene), 6.803--8.042 (m, 11H, Ar-H) 8.390, (s, 1H, CH=N-) group. MS: m/z 367. Anal. Calculated for C~24~ H~21~ N~3~ O: C 78.45, H 5.76, N 11.44%.Found: C 78.62, H 5.58, N 11.52%.

3.3. Synthesis of 4-(2-methylquinoxalin-3-yloxy)-benzamine *(**6**)*
--------------------------------------------------------------------

4-Aminophenol (1.09 g, 0.01 M) was dissolved in a mixture of acetonitrile (50 mL) and DMF (10 mL) containing anhydrous K~2~CO~3~ (2.0 g). The mixture was refluxed for 1 hour then of 2-chloro-3-methylquinoxaline (1.785 g, 0.01 M) was added and mixture was further refluxed for 30 hour. The mixture was filtered and the excess of acetonitrile was distilled off to get the product. The crude product was treated with 2% NaOH solution to dissolve any unreacted 4-aminophenol. The product was filtered, washed with distilled water to remove traces of alkali and recrystallized from ethanol to give crystals of 4-(2-methylquinoxaline-3yloxy)-benzamine, yield 65%; m.p. 178 °C; IR (KBr, cm^−1^): 3,466 and 3,426 (1° amine group N-H), 3,041 (methyl group C-H), 1,620 (C=N) and 1,221 (ether C-O); ^1^H-NMR (CDCl~3~): 2.825 (s, 3H, CH~3~ attached to quinoxaline ring), 3.742(s, 2H, NH~2~ protons, which were D~2~O exchangeable) 6.77--8.00 (m, 8H, Ar-H)

3.4. General procedure for the synthesis of 4-(2-methylquinoxalin-3-yloxy)-N-substituted benzylidine benzamines **7a--e**
-------------------------------------------------------------------------------------------------------------------------

A mixture of equalmolar quantities of compound **6** (0.01 M) and aromatic aldehydes (0.01 M) in ethanol (25 mL) containing a catalytic amount of glacial acetic acid were refluxed for sufficient time to complete the reaction, as monitored by TLC. The products so obtained were filtered, washed and recrystallized from appropriate solvents.

### 3.4.1. 4-\[-{4-(2-Methylquinoxalin-3-yloxy)-phenyl}-iminomethyl\]-phenol (**7a**)

IR (KBr, cm^−1^): 3,400 (phenol O-H), 3,065 (methyl C-H), 1,584, (-N=CH), 1,250 (ether C-O) and at 1,205 (phenol C-O). ^1^H NMR (CDCl~3~): 2.840 (s, 3H, CH~3~ attached to quinoxaline ring), 5.024 (s, 1H, Ar-OH), 6.861--8.052 (m, 12H, Ar-H), 9.031 (s, 1H, CH=N-). MS: m/z 355. Anal. Calculated for C~22~ H~17~ N~3~ O~2~: C, 74.35; H, 4.82; N, 11.82%.Found: C 74.15, H 5.00, N 12.05%.

### 3.4.2. 4-(2-methylquinoxalin-3-yloxy)-N-(2-nitrobenzylidene)-benzamine (**7b**)

IR (KBr, cm^−1^): 3,060 (methyl C-H), 1,572 (-N=CH), 1,518 and 1,340 (aromatic nitro group -O-N=O & C-N), 1,223 (ether C-O). ^1^H NMR (CDCl~3~): 2.842 (s, 3H, CH~3~ attached to quinoxaline ring), 7.261--8.359 (m, 12H, Ar-H), 9.031, (s, 1H, CH=N-). MS: m/z 384. Anal. Calculated for C~22~ H~16~ N~4~ O~3~: C 68.74, H 4.20, N 14.58%.Found: C 68.58, H 4.00, N 14.75%.

### 3.4.3. 4-\[-{4-(2-Methylquinoxalin-3-yloxy)-phenyleneimino}-methyl\]-N-dimethylbenzamine (**7c**)

IR (KBr, cm^−1^): 2,928 (methyl C-H), 1,590 (-N=CH), 1,329 (tertiary amine C-N),1,226 (ether C-O). ^1^H NMR (CDCl~3~): 2.835 (s, 3H, CH~3~ attached to quinoxaline ring), 3.025 (s, 6H, CH~3~ protons of 3° amine), 7.028--8.212 (m, 12H, Ar-H), 8.516 (s, 1H, CH=N-). MS: m/z 382. Anal. Calculated for C~24~ H~22~ N~4~ O: C 75.37, H 5.80, N 14.65%.Found: C 75.60, H, 5.65, N 14.80%.

### 3.4.4. \[{4-(2-Methylquinoxaline-3-yloxy)-phenyleneimino}-methyl\]-6-methoxyphenol (**7d**)

IR (KBr, cm^−1^): 3,450 and 1192 (phenol O-H & C-O), 3,060 (methyl C-H), 1,580 (-N=CH), 1,192 and 1,011 (methoxy C-O), 1223 (ether C-O). ^1^H NMR (CDCl~3~): 2.841 (s, 3H, CH~3~ attached to quinoxaline ring), 3.960 (s, 3H, --OCH~3~), 5.124 (s, 1H, phenolic--OH), 6.887--8.001 (m, 11H, Ar-H), 8.702 (s, 1H, CH=N-). MS: m/z 385. Anal. Calculated for C~23~ H~19~ N~3~ O~3~: C 71.67, H 4.97, N 10.90%. Found: C 71.56, H 4.80, N 11.05%.

### 3.4.5. 4-(2-Methylquinoxalin-3-yloxy)-n-(3, 4, 5-trimethoxybenzylidene)-benzamine (**7e**)

IR (KBr, cm^−1^): 2,941, (methyl C-H), 1,579 (-N=CH), 1,199 and 999, (methoxy C-O), 1,226 (ether C-O). ^1^H NMR (CDCl~3~): 2.838 (s, 3H, CH~3~ attached to quinoxaline ring), 3.934--3.971 (t, 9H, OCH~3~), 6.887--7.998(m, 10H, Ar-H), 8.441 (s, 1H, CH=N-) group. MS: m/z 429. Anal. Calculated for C~25~ H~23~ N~3~ O~4~: C 69.92, H 5.40, N 9.78%.Found: C 70.20, H 5.15, N 9.95%. All the synthesized compounds were purified by recrystallization from appropriate solvent monitored by TLC. The list of all the synthesized compounds is shown in the [Table 2](#pharmaceuticals-03-02416-t002){ref-type="table"}.

3.5. Antibacterial Activity
---------------------------

The antibacterial activity was assayed by agar plate disc diffusion method \[[@B18-pharmaceuticals-03-02416]\] at the concentration of 50 µg per disk. All the synthesized compounds were tested *in vitro* for their antibacterial activity against microorganisms such as *Staphylococcus aureus*, *Bacillus subtilis* (gram positive), *Escherichia coli*, *and Pseudomonas aerugenosa* (gram negative) strains. Each test compounds were dissolved in dimethylsulphoxide (DMSO) to get a concentration of 10 mg/mL. The disc (6 mm in diameter) was impregnated with 5 µL of each test solution to get 50 µg/disc, air dried and placed on the agar medium, previously seeded with 0.2 mL of broth culture of each organism for 18 hours. The plates were incubated at 37 °C for 24 hours and the inhibition zones measured in mm. Discs impregnated with DMSO were used as a control and ciprofloxacin discs as antibacterial reference standard.

pharmaceuticals-03-02416-t002_Table 2

###### 

Reaction conditions and physical data of synthesized compounds.

  Compounds   R                  Reaction Time   Crystallization Solvents   M.P. (°C)   Mobile phase                      R~f~ value
  ----------- ------------------ --------------- -------------------------- ----------- --------------------------------- ------------
  **4**       \-                 30 hours        Ethanol                    116--117    Ethyl acetate: *n*-Hexane (1:1)   0.72
  **5a**      H                  10 hours        Ethanol                    140         Ethyl acetate: n-Hexane (1:1)     0.80
  **5b**      2-Cl               17 hours        Ethanol                    142         Ethyl acetate: n-Hexane (1:1)     0.78
  **5c**      4-CH~3~            9 hours         Ethanol                    159--160    Ethyl acetate                     0.75
  **5d**      4-COOH             16 hours        Ethanol                    221--222    Ethyl acetate: n-Hexane (1:1)     0.50
  **5e**      2-CH~3~,6-CH~3~    5 hours         Ethanol                    131--132    Ethyl acetate                     0.87
  **6**       \-                 30 hours        Ethanol                    178         Ethyl acetate: n-Hexane (1:1)     0.70
  **7a**      4-OH               6 hours         Ethanol                    220         Ethyl acetate: n-Hexane (1:1)     0.60
  **7b**      2-NO~2~            1 hours         Ethanol                    171--172    Ethyl acetate: n-Hexane (1:1)     0.77
  **7c**      4-N(CH~3~)2        15 hours        Ethanol                    220         Ethyl acetate: n-Hexane (1:1)     0.70
  **7d**      2-OH,3-OCH~3~      1 hours         Ethanol                    190         Ethyl acetate: n-Hexane (1:1)     0.85
  **7e**      3,4,5(OCH~3~)~3~   21 hours        Ethanol                    135         Ethyl acetate: n-Hexane (1:1)     0.65

3.6. Antifungal Activity
------------------------

The antifungal activity \[[@B19-pharmaceuticals-03-02416]\] was assayed by the Sabouraud dextrose agar media plate disc diffusion method at a concentration of 50 µg per disk. All the synthesized compounds were tested *in vitro* for their antifungal activity against microorganisms such as *Aspergillus niger* and *Candida albicans*. Each test compound was dissolved in dimethylsulphoxide (DMSO) to get a concentration of 10 mg/mL. The disc (6 mm in diameter) was impregnated with 5 µL of each test solution to get 50 µg/disc; air dried and placed on the Sabouraud dextrose agar media, previously seeded with 0.2 mL of broth culture of each organism for 18 hours. The plates were incubated at 22 °C for 48 hours and the inhibition zones measured in mm. Discs impregnated with DMSO were used as a negative control and fluconazole discs as antifungal reference standard. The results have already been shown are in [Table 1](#pharmaceuticals-03-02416-t001){ref-type="table"}.
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